LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 1490

Search options

  1. Book: The use of statins in people at risk of developing diabetes mellitus

    Sattar, Naveed

    evidence and guidance for clinical practice

    (Atherosclerosis : Supplements ; 15,1)

    2014  

    Author's details [Naveed A. Sattar ...]
    Series title Atherosclerosis : Supplements ; 15,1
    Atherosclerosis
    Atherosclerosis ; Supplements
    Collection Atherosclerosis
    Atherosclerosis ; Supplements
    Language English
    Size 15 S. : graph. Darst.
    Publisher Elsevier
    Publishing place Amsterdam u.a.
    Publishing country Netherlands
    Document type Book
    HBZ-ID HT018323682
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 226 -Suppl.15,1- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: There is no evidence that vitamin D prevents cardiovascular events.

    Sattar, Naveed

    BMJ (Clinical research ed.)

    2023  Volume 382, Page(s) 1765

    MeSH term(s) Humans ; Vitamin D/therapeutic use ; Vitamins/therapeutic use ; Vitamin D Deficiency/complications ; Vitamin D Deficiency/prevention & control ; Cardiovascular Diseases/prevention & control ; Dietary Supplements ; Risk Factors
    Chemical Substances Vitamin D (1406-16-2) ; Vitamins
    Language English
    Publishing date 2023-08-01
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 1362901-3
    ISSN 1756-1833 ; 0959-8154 ; 0959-8146 ; 0959-8138 ; 0959-535X ; 1759-2151
    ISSN (online) 1756-1833
    ISSN 0959-8154 ; 0959-8146 ; 0959-8138 ; 0959-535X ; 1759-2151
    DOI 10.1136/bmj.p1765
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.10: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Statins and diabetes: What are the connections?

    Sattar, Naveed

    Best practice & research. Clinical endocrinology & metabolism

    2023  Volume 37, Issue 3, Page(s) 101749

    Abstract: Randomized trials suggest moderate-intensity statins increase type 2 diabetes risk by around 11% with a potential further 12% moving to high-intensity statins, such that high intensity may increase risk by 20% or more relative to placebo. These data ... ...

    Abstract Randomized trials suggest moderate-intensity statins increase type 2 diabetes risk by around 11% with a potential further 12% moving to high-intensity statins, such that high intensity may increase risk by 20% or more relative to placebo. These data translate into one extra diabetes case per 100-200 statin recipients over 5 years, with ∼10-fold greater benefits on major vascular outcomes. The underlying mechanisms for diabetes harm are not clear but could include modest weight gain (noted in randomized trials), or, speculatively, beta cell harm. Concordant genetic studies link HMG CoA Reductase inhibition to diabetes risk and weight gain. Patients should be warned about a slight diabetes risk when prescribed statin and told that modest lifestyle improvements can i) nullify diabetes risk, and ii) improve cardiovascular risks beyond statins. Doctors should also measure glycemia status post statin commencement, most commonly with HbA1c, and tailor lifestyle advice and care dependent on the results.
    MeSH term(s) Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Diabetes Mellitus, Type 2/drug therapy ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/prevention & control ; Life Style
    Chemical Substances Hydroxymethylglutaryl-CoA Reductase Inhibitors
    Language English
    Publishing date 2023-02-15
    Publishing country Netherlands
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2052339-7
    ISSN 1878-1594 ; 1532-1908 ; 1521-690X
    ISSN (online) 1878-1594 ; 1532-1908
    ISSN 1521-690X
    DOI 10.1016/j.beem.2023.101749
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 1075: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Book: ABC of obesity

    Sattar, Naveed

    (ABC series ; BMJ books)

    2007  

    Author's details ed. by Naveed Sattar
    Series title ABC series
    BMJ books
    Language English
    Size IX, 50 S. : Ill., graph. Darst., 28cm
    Publisher Blackwell
    Publishing place Oxford u.a.
    Publishing country Great Britain
    Document type Book
    Note Obesity--time to wake up / David Haslam, Naveed Sattar, Mike Lean -- Assessment of obesity and its clinical implications / Thang S. Han, Naveed Sattar, Mike Lean -- Management : part I--behaviour change, diet, and activity / Alison Avenell, Naveed Sattar, Mike Lean -- Management : part II--drugs / Mike Lean, Nick Finer -- Management : part III--surgery / John G. Kral -- Strategies for preventing obesity / Mike Lean, Jose Lara, James O. Hill -- Risk factors for diabetes and coronary heart disease / Sarah H. Wild, Christopher D. Byrne -- Obesity and vascular disease / Debbie A. Lawlor, Mike Lean, Naveed Sattar -- Obesity and cancer / Donald C. McMillan ... [et al.] -- Obesity and reproduction / Jane E. Ramsay, Ian Greer, Naveed Sattar -- Childhood obesity / John J. Reilly, David Wilson -- Obesity--can we turn the tide? / Mike Lean ... [et al.]. - Includes bibliographical references and index. - Formerly CIP
    HBZ-ID HT015400880
    ISBN 978-1-405-13674-7 ; 978-1-4051-3674-7 ; 1-4051-3674-X ; 1-405-13674-X
    Database Catalogue ZB MED Nutrition, Environment, Agriculture

    More links

    Kategorien

    In stock of ZB MED Bonn / Germany

    Shelf markLoan statusLocation
    074/749 available for loan (reading room) Freihandmagazin (U1)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Prevention of Diabetes Macrovascular Complications and Heart Failure.

    Sattar, Naveed

    Endocrinology and metabolism clinics of North America

    2021  Volume 50, Issue 3, Page(s) 415–430

    Abstract: Cardiovascular (CV) mortality in diabetes has declined substantially over the last 3 decades in high-income countries from a multifactorial approach targeting glucose, cholesterol, and blood pressure, and lower smoking rates. Additional CV gains may be ... ...

    Abstract Cardiovascular (CV) mortality in diabetes has declined substantially over the last 3 decades in high-income countries from a multifactorial approach targeting glucose, cholesterol, and blood pressure, and lower smoking rates. Additional CV gains may be achieved from large-scale weight loss, which ongoing trials are testing, and from delaying diabetes in those at highest risk. Finally, recent outcome trials support a role for (1) sodium/glucose cotransporter-2 inhibitors, which lower major adverse cardiovascular events but incident heart failure more strongly, and (2) glucagon-like peptide-1 receptor agonists, which lower atherothrombotic outcomes more consistently, including stroke and peripheral arterial disease.
    MeSH term(s) Cardiovascular Diseases/prevention & control ; Diabetes Mellitus, Type 2/complications ; Glucagon-Like Peptide-1 Receptor/agonists ; Heart Failure/etiology ; Heart Failure/prevention & control ; Humans ; Hypoglycemic Agents/pharmacology ; Sodium-Glucose Transporter 2 Inhibitors/pharmacology ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
    Chemical Substances Glucagon-Like Peptide-1 Receptor ; Hypoglycemic Agents ; Sodium-Glucose Transporter 2 Inhibitors
    Language English
    Publishing date 2021-07-12
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 92116-6
    ISSN 1558-4410 ; 0889-8529
    ISSN (online) 1558-4410
    ISSN 0889-8529
    DOI 10.1016/j.ecl.2021.05.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 148: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Book: Statins are diabetogenic - myth or reality?

    Sattar, Naveed / Taskinen, Marja-Riitta

    (Atherosclerosis : Supplements ; 13,1)

    2012  

    Author's details [Naveed Sattar ; Marja-Riitta Taskinen]
    Series title Atherosclerosis : Supplements ; 13,1
    Atherosclerosis
    Atherosclerosis ; Supplements
    Collection Atherosclerosis
    Atherosclerosis ; Supplements
    Language English
    Size 10 S. : Ill., graph. Darst.
    Publisher Elsevier
    Publishing place Amsterdam u.a.
    Publishing country Netherlands
    Document type Book
    HBZ-ID HT017432518
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 226 -Suppl.13,1- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Identifying Patients with Nonalcoholic Fatty Liver Disease in Primary Care: How and for What Benefit?

    Schreiner, Andrew D / Sattar, Naveed

    Journal of clinical medicine

    2023  Volume 12, Issue 12

    Abstract: Despite its increasing prevalence, nonalcoholic fatty liver disease (NAFLD) remains under-diagnosed in primary care. Timely diagnosis is critical, as NAFLD can progress to nonalcoholic steatohepatitis, fibrosis, cirrhosis, hepatocellular carcinoma, and ... ...

    Abstract Despite its increasing prevalence, nonalcoholic fatty liver disease (NAFLD) remains under-diagnosed in primary care. Timely diagnosis is critical, as NAFLD can progress to nonalcoholic steatohepatitis, fibrosis, cirrhosis, hepatocellular carcinoma, and death; furthermore, NAFLD is also a risk factor linked to cardiometabolic outcomes. Identifying patients with NAFLD, and particularly those at risk of advanced fibrosis, is important so that healthcare practitioners can optimize care delivery in an effort to prevent disease progression. This review debates the practical issues that primary care physicians encounter when managing NAFLD, using a patient case study to illustrate the challenges and decisions that physicians face. It explores the pros and cons of different diagnostic strategies and tools that physicians can adopt in primary care settings, depending on how NAFLD presents and progresses. We discuss the importance of prescribing lifestyle changes to achieve weight loss and mitigate disease progression. A diagnostic and management flow chart is provided, showing the key points of assessment for primary care physicians. The advantages and disadvantages of advanced fibrosis risk assessments in primary care settings and the factors that influence patient referral to a hepatologist are also reviewed.
    Language English
    Publishing date 2023-06-12
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm12124001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Diabetes management gains: teaching old dogs new tricks.

    Sattar, Naveed

    Diabetic medicine : a journal of the British Diabetic Association

    2019  Volume 36, Issue 9, Page(s) 1072–1074

    MeSH term(s) Cardiovascular System ; Consensus ; Diabetes Mellitus, Type 2 ; Humans ; United Kingdom
    Language English
    Publishing date 2019-08-01
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 605769-x
    ISSN 1464-5491 ; 0742-3071 ; 1466-5468
    ISSN (online) 1464-5491
    ISSN 0742-3071 ; 1466-5468
    DOI 10.1111/dme.14068
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1954: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention.

    Wong, Nathan D / Sattar, Naveed

    Nature reviews. Cardiology

    2023  Volume 20, Issue 10, Page(s) 685–695

    Abstract: Cardiovascular diseases (CVDs) are the leading causes of morbidity and mortality in individuals with type 2 diabetes mellitus (T2DM). Secular changes in CVD outcomes have occurred over the past few decades, mainly due to a decline in the incidence of ... ...

    Abstract Cardiovascular diseases (CVDs) are the leading causes of morbidity and mortality in individuals with type 2 diabetes mellitus (T2DM). Secular changes in CVD outcomes have occurred over the past few decades, mainly due to a decline in the incidence of ischaemic heart disease. The onset of T2DM at a young age (<40 years), leading to a greater number of life-years lost, has also become increasingly common. Researchers are now looking beyond established risk factors in patients with T2DM towards the role of ectopic fat and, potentially, haemodynamic abnormalities in mediating important outcomes (such as heart failure). T2DM confers a wide spectrum of risk and is not necessarily a CVD risk equivalent, indicating the importance of risk assessment strategies (such as global risk scoring, consideration of risk-enhancing factors and assessment of subclinical atherosclerosis) to inform treatment. Data from epidemiological studies and clinical trials demonstrate that successful control of multiple risk factors can reduce the risk of CVD events by ≥50%; however, only ≤20% of patients achieve targets for risk factor reduction (plasma lipid levels, blood pressure, glycaemic control, body weight and non-smoking status). Improvements in composite risk factor control with lifestyle management (including a greater emphasis on weight loss interventions) and evidence-based generic and novel pharmacological therapies are therefore needed when the risk of CVD is high.
    MeSH term(s) Humans ; Adult ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/epidemiology ; Risk Factors ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/prevention & control ; Coronary Artery Disease ; Heart Disease Risk Factors ; Risk Assessment
    Language English
    Publishing date 2023-05-16
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2490375-9
    ISSN 1759-5010 ; 1759-5002
    ISSN (online) 1759-5010
    ISSN 1759-5002
    DOI 10.1038/s41569-023-00877-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6019: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 98: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: A review of current key guidelines for managing high-risk patients with diabetes and heart failure and future prospects.

    Lee, Matthew M Y / Sattar, Naveed

    Diabetes, obesity & metabolism

    2023  Volume 25 Suppl 3, Page(s) 33–47

    Abstract: We reviewed recent guidelines on the management of heart failure (HF) in patients with diabetes. Major recommendations in European and US society guidelines were scrutinized. First, sodium-glucose co-transporter 2 inhibitors are now recommended ... ...

    Abstract We reviewed recent guidelines on the management of heart failure (HF) in patients with diabetes. Major recommendations in European and US society guidelines were scrutinized. First, sodium-glucose co-transporter 2 inhibitors are now recommended treatments for all patients with symptomatic HF (stage C and D; New York Heart Association class II-IV), irrespective of the presence of type 2 diabetes and left ventricular ejection fraction (LVEF). Second, patients with HF and reduced EF (LVEF ≤40%) should have foundational therapies from four drug classes (sodium-glucose co-transporter 2 inhibitor, angiotensin-receptor neprilysin inhibitor, beta-blocker and mineralocorticoid receptor antagonist). Third, patients with HF with mildly reduced (41%-49%) and preserved (≥50%) LVEF may also benefit from angiotensin-receptor neprilysin inhibitor, beta-blocker and mineralocorticoid receptor antagonist therapy, although evidence for these is less robust. Fourth, selected patients should be considered for other therapies such as diuretics (if congestion), anticoagulation (if atrial fibrillation) and cardiac device therapy. Fifth, glucose-lowering therapies such as thiazolidinediones and certain dipeptidyl peptidase-4 inhibitors (such as saxagliptin and alogliptin) should be avoided in patients with HF. Sixth, guidelines recommend enrolment of patients with HF into exercise rehabilitation and multidisciplinary HF management programmes. Particular attention should be paid to important comorbidities such as obesity, alongside pharmacological therapies. As diabetes and obesity are major risk factors for HF, earlier consideration of, and diagnosis of HF, followed by guideline-directed medical therapy can meaningfully improve patients' lives. Diabetes doctors would do well to understand the basics of such guidelines to help improve all aspects of HF diagnosis and care.
    MeSH term(s) Humans ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/epidemiology ; Stroke Volume ; Mineralocorticoid Receptor Antagonists/therapeutic use ; Neprilysin ; Ventricular Function, Left ; Heart Failure/therapy ; Heart Failure/drug therapy ; Adrenergic beta-Antagonists/therapeutic use ; Obesity/drug therapy ; Glucose/therapeutic use ; Symporters/therapeutic use ; Angiotensins/therapeutic use ; Sodium ; Angiotensin Receptor Antagonists/therapeutic use
    Chemical Substances Mineralocorticoid Receptor Antagonists ; Neprilysin (EC 3.4.24.11) ; Adrenergic beta-Antagonists ; Glucose (IY9XDZ35W2) ; Symporters ; Angiotensins ; Sodium (9NEZ333N27) ; Angiotensin Receptor Antagonists
    Language English
    Publishing date 2023-05-30
    Publishing country England
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 1454944-x
    ISSN 1463-1326 ; 1462-8902
    ISSN (online) 1463-1326
    ISSN 1462-8902
    DOI 10.1111/dom.15085
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5442: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top